Trial Profile
A Phase 3, Randomized, Double-blind,Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Registrational; Therapeutic Use
- Acronyms OASIS (EM); OASIS PEDIATRIC [EM]
- Sponsors Amgen
- 06 Sep 2023 Planned End Date changed from 5 May 2027 to 29 Jul 2027.
- 06 Sep 2023 Planned primary completion date changed from 6 May 2026 to 17 Jun 2026.
- 01 Feb 2023 Planned End Date changed from 29 Jul 2027 to 5 May 2027.